Akihito Inagaki

Data from Measles Oncolytic Virus as an Immunotherapy for Recurrent/Refractory Pediatric Medulloblastoma and Atypical Teratoid/Rhabdoid Tumor: Results from PNOC005

Bohyeon Yu, Cassie Kline, Owen Hoare, Jangham Jung et autres

AbstractPurpose: Pediatric recurrent medulloblastoma and atypical teratoid/rhabdoid tumor (ATRT) are largely incurable and warrant novel therapies. PNOC005 is a phase I clinical trial investigating the safety and tolerability of intratumoral or intrathecal administration of oncolytic measles virus (MV-NIS) in children and young …

Measles Oncolytic Virus as an Immunotherapy for Recurrent/Refractory Pediatric Medulloblastoma and Atypical Teratoid/Rhabdoid Tumor: Results from PNOC005

Bohyeon Yu, Cassie Kline, Owen Hoare, Jangham Jung et autres

PURPOSE: Pediatric recurrent medulloblastoma and atypical teratoid/rhabdoid tumor (ATRT) are largely incurable and warrant novel therapies. PNOC005 is a phase I clinical trial investigating the safety and tolerability of intratumoral or intrathecal administration of oncolytic measles virus (MV-NIS) in children and young …

us, ch (code pays fourni par la source)

Abstract 474: IL-12 immunotherapy using a novel gene delivery platform for RNA payloads achieves effective antitumor responses without systemic toxicity in an aggressive CT26 murine cancer model

Laura Strauss, Akihito Inagaki, Stephanie Lees, Noriyuki Kasahara et autres

Background: IL-12 exhibits potent anti-tumor properties, which enhance cytolytic activity and tumor infiltration of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) and activates Th-1-type immune responses [1-2]. However, systemic administration of recombinant IL-12 protein is still a challenge due to …

us (code pays fourni par la source)

HLA-Pan-DP CAR-T Demonstrates Cytotoxicity Against Multiple Hematological Malignancies

Hiroyuki Takamatsu, Emilio Ramos, Bonell Patiño-Escobar, Corynn Kasap et autres

Background: Relapse of hematological malignancies often originates from residual cancer and/or its initiating cells. Target antigens on cells, such as CD19 and BCMA, are often downregulated after immunotherapy (Orlando et al., Nature Medicine 2018; Dhodapkar et al., Blood Cancer Discovery 2022). In …

jp, us (code pays fourni par la source)

Therapeutic activity of retroviral replicating vector-mediated gene therapy in combination with anti-PD-1 antibody in a murine pancreatic cancer model

Hiroki Niwa, Toru Nakamura, Hiroki Kushiya, Tomotaka Kuraya et autres

jp, us (code pays fourni par la source)

IMMU-09. DISSECTING THE INTERPLAY BETWEEN THE ENDOGENOUS IMMUNE RESPONSE AND ONCOLYTIC VIRUS THERAPY IN PEDIATRIC BRAIN TUMORS

Owen Hoare, Jangham Jung, Akihito Inagaki, Bohyeon Yu et autres

Abstract Oncolytic virus (OV) elicits an antitumor immune response in addition to tumor-cell killing. However, it is unknown if a pre-existing antitumor immune response aids or hinders OV therapy. To study the interplay between the endogenous immune response and OV we profiled …

us (code pays fourni par la source)

Supplementary Table 3 from Combined Alloreactive CTL Cellular Therapy with Prodrug Activator Gene Therapy in a Model of Breast Cancer Metastatic to the Brain

Michelle J. Hickey, Colin C. Malone, Kate L. Erickson, Amy Lin et autres

PDF file - 282K, Biodistribution of RRV in brain / brain tumor and other tissues derived from animals within Figure 6 treatment groups.

Supplementary Figure 3 from Combined Alloreactive CTL Cellular Therapy with Prodrug Activator Gene Therapy in a Model of Breast Cancer Metastatic to the Brain

Michelle J. Hickey, Colin C. Malone, Kate L. Erickson, Amy Lin et autres

PDF file - 1480K, Clinical study design formulated for immunogene therapy of brain metastases.

Supplementary Figure Legend from Combined Alloreactive CTL Cellular Therapy with Prodrug Activator Gene Therapy in a Model of Breast Cancer Metastatic to the Brain

Michelle J. Hickey, Colin C. Malone, Kate L. Erickson, Amy Lin et autres

PDF file - 73K

Supplementary Table 1 from Combined Alloreactive CTL Cellular Therapy with Prodrug Activator Gene Therapy in a Model of Breast Cancer Metastatic to the Brain

Michelle J. Hickey, Colin C. Malone, Kate L. Erickson, Amy Lin et autres

PDF file - 114K, HLA-ABC expression on human breast cancer cell lines with and without IFNγ incubation.

Supplementary Table 2 from Combined Alloreactive CTL Cellular Therapy with Prodrug Activator Gene Therapy in a Model of Breast Cancer Metastatic to the Brain

Michelle J. Hickey, Colin C. Malone, Kate L. Erickson, Amy Lin et autres

PDF file - 130K, HLA class I types of 231 stimulator cells and of the allodonors supplying precursor alloCTL for the experimental studies.

Supplementary Figure 1 from Combined Alloreactive CTL Cellular Therapy with Prodrug Activator Gene Therapy in a Model of Breast Cancer Metastatic to the Brain

Michelle J. Hickey, Colin C. Malone, Kate L. Erickson, Amy Lin et autres

PDF file - 409K, Individual animal weights plotted over time for treatment groups shown in Figure 6.